The Safety Data Gap
Some peptides (semaglutide, tirzepatide) have gone through full FDA clinical trials with thousands of participants. Others (BPC-157, TB-500, MOTS-c) have mostly animal data and user reports. Your confidence in the safety profile should match the amount of data behind it.
This guide lists the side effects that show up most often, organized by peptide category. The per-category lists are the most useful part. Read the section for whatever you're taking.
Side Effects by Category
GLP-1 Agonists: Semaglutide and Tirzepatide
These are the best-studied peptides on this list. Both are FDA-approved for diabetes and weight management, so there's real clinical trial data behind them.
Common side effects:
- Nausea (the Wegovy USPI §6.1 reported ~44% in STEP 1; Mounjaro USPI §6.1 reported 24-33% across the dose range; typically highest during dose escalation)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- Decreased appetite
Nausea is worst during the first 4-6 weeks and during dose increases. It usually fades. Semaglutide starts at 0.25mg weekly and titrates up to 1-2.5mg. Tirzepatide starts at 2.5mg weekly and goes up to 15mg, increasing no sooner than every 4 weeks.
Serious but less common risks:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems including gallstones
- Kidney injury (often related to dehydration from GI symptoms)
- Increased heart rate
- Thyroid C-cell tumors (boxed warning on Wegovy/Ozempic/Mounjaro/Zepbound labels; mechanism studied in Bjerre Knudsen, Endocrinology 2010; clinical relevance in humans is debated but contraindicated with personal/family history of medullary thyroid carcinoma or MEN-2)
Growth Hormone-Releasing Peptides
This covers CJC-1295/Ipamorelin, Sermorelin, and HGH.
Common side effects:
- Injection site discomfort
- Headaches
- Water retention (transient)
- Flushing or warmth
- Numbness/tingling sensations
At standard doses (CJC-1295: 100-300mcg daily; Ipamorelin: 100-200mcg 1-3 times daily), most people tolerate these well. Higher doses can cause:
- Increased appetite
- Joint pain
- Carpal tunnel-like symptoms
- Insulin resistance with excessive use
If you have any blood sugar issues, monitor glucose while on GH-releasing peptides. GH and IGF-1 both affect insulin sensitivity.
Tissue Repair Peptides
BPC-157 and TB-500. These have limited human data. Most safety information comes from animal studies and user reports.
Reported side effects (generally mild):
- Injection site reactions (most common)
- Temporary nausea
- Headaches
- Dizziness
BPC-157 runs at 250-500mcg daily. TB-500 runs at 2.0-2.5mg per week, sometimes with a 4-6mg loading phase for the first 2 weeks.
Metabolic Peptides
AOD-9604 is a modified GH fragment that targets fat metabolism without growth effects. MOTS-c is a mitochondrial-derived peptide that activates AMPK for metabolic regulation.
Reported side effects (minimal for both):
- Injection site reactions
- Mild headaches
- Occasionally joint pain (AOD-9604)
- Nausea (MOTS-c, less common)
AOD-9604 standard dosing is 250-500mcg daily. MOTS-c is typically 5-10mg, 3-5x weekly. Neither has extensive human safety data.
Neuroactive Peptides
Common side effects:
- Headaches (particularly with Semax at higher doses)
- Mood changes
- Sleep pattern changes
- Injection site reactions
Semax: 500-1000mcg daily, intranasal or subcutaneous. PT-141: 1-2mg as needed (nausea is the main complaint). DSIP and GHK-Cu have mild profiles, mostly just injection site discomfort.
Reducing Side Effects
Start Low, Increase Slowly
This is the single most effective thing you can do. For any new peptide:
- Start at the low end of the dose range
- Wait 3-7 days before increasing
- Go up in 25-50% increments
- Stop increasing once you're getting the effect you want
Injection Technique
- Rotate sites (abdomen, thigh, upper arm)
- Go subcutaneous, not intramuscular, unless the protocol specifically calls for IM
- 45-90 degree angle depending on body fat at the site
- Ice for 1-2 minutes before injecting if you're sensitive
Timing
- GLP-1 peptides (semaglutide, tirzepatide): empty stomach or bedtime
- GH secretagogues: fasted, 30-60 minutes before meals
- Multiple peptides on the same day: space them out
Monitoring
- Keep a simple log of what you take and any symptoms
- Stay hydrated, especially on GLP-1 agonists (nausea and GI issues cause fluid loss)
- Check blood glucose if you're on GH-releasing peptides
- Get bloodwork before starting and every 8-12 weeks on longer protocols
When to Stop
Stop immediately and get medical attention if you experience:
- Severe or persistent abdominal pain (possible pancreatitis)
- Persistent vomiting or inability to keep fluids down
- Signs of allergic reaction: hives, swelling, breathing difficulty
- Rapid heartbeat or palpitations
- Yellowing of skin or eyes (possible liver issues)
- Unexplained swelling in hands or feet
- Injection site spreading redness, warmth, or pus (infection)
Stop and talk to a provider (not an emergency, but don't keep dosing) for:
- Persistent headache lasting more than 24 hours
- Nausea bad enough to affect normal activities
- Mood changes or mental health symptoms
- Any new symptoms that show up after the initial adjustment period (first 1-2 weeks)
References
- Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021. PubMed
- Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 2022. PubMed
Disclaimer: Peptide use carries real risks that vary by compound, dose, and individual factors. Consult a healthcare provider before starting any peptide protocol.